Hyperbaric Chamber Relief After Chemotherapy

Hyperbaric Chamber Relief After Chemotherapy

University of Gothenburg

1 month
9 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Nicklas Oscarsson of @goteborgsuni on how oxygen in hyperbaric chamber provides relief after radiotherapy affects clinicians and treatment today.

________

Hyperbaric oxygen therapy (HBOT) in the pelvic region, a study shows, can relieve self-reported symptoms and side effects of radiotherapy against cancer. Most patients reported reductions in vomiting, urinary incontinence and discomfort following 30–40 sessions in a hyperbaric chamber.

“This treatment is highly effective for the majority of the patients” states Nicklas Oscarsson, first author of the article, a doctoral student in anesthesiology and intensive care at Sahlgrenska Academy, University of Gothenburg, and senior consultant at Angered Hospital.

Radiation therapy is part of many cancer treatment procedures for organs like the heart, cervix, ovaries, and colon. In the lower abdomen, one side effect of radiotherapy is damage to nearby healthy tissue such as the urinary tract, bladder, vagina, or rectum.

Symptoms such as frequent urination, incontinence, vomiting, and severe abdominal pain cause physical as well as social problems. These can occur several years after radiation therapy and cause chronic pain that often increases. Temporary relief of symptoms or mutilating surgery can often be offered to all of these patients.

Read here: https://www.oncologytube.com/video/after-radiotherapy-oxygen-provides-relief-in-hyperbaric-chamber

Up Next Autoplay
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Category: Chronic Lymphocytic Leukemia
4 Views
ash 6 hours
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
Category: Other
0 Views
ash 6 hours
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Category: Multiple Myeloma
0 Views
ash 23 hours
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of  Hematology (ASH) 2019 Annual Meeting
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
Category: Immunotherapy
2 Views
cancernewsupdate 1 day
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
Category: Immunotherapy
1 Views
ash 1 day
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
2 Views
cancernewsupdate 1 day
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 1 day
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 1 day
Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients #ASH19
Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients #ASH19
Category: General
2 Views
ash 1 day
Safety and Effectiveness of Apixaban #ASH19
Safety and Effectiveness of Apixaban #ASH19
Category: General
1 Views
ash 1 day